HomeTrading IdeasThe Powell-Trump Clash is...

The Powell-Trump Clash is Set to Escalate

Growth challenges are mounting while tariffs will lift inflation, but stagflation fears are wide of the mark. The Fed will likely delay rate cuts until the end of the year, despite escalating pressure from the president, but may move in larger steps when it does cut

Consumer Caution Weighs on Growth

2025 and 2026 consensus forecasts for growth have fallen from 2.2% to 1.5% since the start of the year, with the consumer at the heart of the problem. Sentiment has soured and this has led to consumer spending plateauing over the past six months after having been the engine of growth since the end of the pandemic.

The reasons for this are threefold. Firstly, households quickly recognised that they would be the ones to pay the bulk of the tariff cost despite President Trump declaring that it would be foreigners who pay. With a renewed hike of tariffs on many key trading partners in recent days, the sense that tariff-induced price hikes will squeeze spending power will remain front and centre in consumers’ minds.

Real Consumer Spending Levels Highlight The Lack Of Growth Since December (December 2024 = 100)

Source: Macrobond, ING

Corporate Sector Hurt by Lack of Trade Clarity

At the same time, there is a perception that the jobs market is weakening more significantly than official data suggests. Outside of the private education and healthcare services, government and leisure and hospitality sectors, job creation has virtually stalled and has actually fallen in nine of the past 30 months. Meanwhile, the pick-up in Worker Adjustment and Retraining Notifications (most larger companies have to give 60 days’ notice of upcoming large job losses) suggests that we need to be braced for the threat of increasing numbers of lay-offs and a renewed rise in the unemployment rate through the second half of the year.

Third, the volatility in household wealth is proving to be unsettling. Equities have since regained their 20% losses earlier in the year, but now it is house prices, the largest store of wealth for most Americans, that is becoming an issue. A lack of affordability is now being met by rising inventory for sale, with two consecutive months of price falls already.

This leaves the corporate sector in an uncertain situation, with tariffs and trade further clouding the outlook. This is leading to more subdued investment spending with residential investment looking particularly vulnerable given what is happening to home prices. Second-quarter GDP growth will be lifted by a large unwind of the first quarter import surge caused by businesses front-running tariffs, but that could reverse again in the third quarter, given President Trump’s renewed push for higher tariffs on key trading countries from 1 August.

Tariff-Induced Inflation Will Set Up a Big Clash Between the President and the Fed

Inflation has been well behaved in recent months, posting 0.1% and 0.2% month-on-month readings, but we always suspected it would be three months from April/May before the tariffs show up. That means the July, August and September reports are where we will see the potential 0.4% MoM or even 0.5% prints. President Trump has been pushing the Fed to cut rates by 200bp to 300bp immediately, and two of his appointees to the FOMC from his first presidential term suggested they could vote in favour of a cut as soon as the July . However, the rest of the committee feels they have time to wait, especially in light of the recent firmer-than-expected June jobs report.

The Fed was stung by criticism after suggesting the post-pandemic supply shock price hikes would be “transitory”, only for inflation to hit 9% in 2022. We suspect a majority of FOMC members will want to ensure that tariffs are a one-off price change rather than something that leads to greater permanence in inflation. We doubt they will have enough evidence to be certain of that by the September FOMC meeting, so we would need to see some significant weakness in jobs to trigger a rate hike at that point. That suggests the president’s frustrations with Jerome Powell will intensify, with him set to seek a more dovish replacement for when Powell’s term as Fed Chair ends early next year. Talk of firings may escalate too.

Fed to Wait, but Cut by 50bp in December

Nonetheless, will come. The cooler growth environment with a softer jobs narrative and weakening wage pressures will help ensure that inflation is indeed temporary. Moreover, the shifting dynamics of the housing market will mean housing costs, which have been a major driver of inflation in recent years, will increasingly become a source of disinflationary pressure. With the risk that unemployment does start to climb, we believe the Fed will be much more comfortable with cutting interest rates from the December FOMC meeting, kicking off with a 50bp move.

Our main takeaway in our separate section on the One Big Beautiful Bill Act is that this adds a significant chunk of debt due primarily to making permanent the 2017 Tax Cuts and Jobs Act, but does nothing to boost growth. That’s because the bulk of the legislation merely extends the tax cuts that were due to sunset at the end of this year. Moreover, the additional tax cuts announced (including on tips and overtime) are more than offset by the net spending cuts, largely falling on lower-income households via Medicare and food programmes, plus reduced tax incentives for ESG-related projects. As such, there is a net headwind to growth for 2026 versus 2025 which means that the risks are likely skewed in favour of the Fed having to ease more than we are currently forecasting in 2026, rather than less.

Disclaimer: This publication has been prepared by ING solely for information purposes irrespective of a particular user’s means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Read more

Original Post

Most Popular

More from Author

Gold Prices Rise on Trump’s Tariff Threats and Fed Policy Uncertainty

Tariff-Related Inflation Risks Support Gold Gold () rose by over 0.35% on...

US Dollar Holds Steady as Trump Threatens 50% Tariffs on Brazil

Trump announces fresh round of tariffs on Brazil and smaller nations But...

Read Now

Gold Prices Rise on Trump’s Tariff Threats and Fed Policy Uncertainty

Tariff-Related Inflation Risks Support Gold Gold () rose by over 0.35% on Wednesday. Markets remain focused on tariff demand letters from US President Donald Trump, with Brazil the latest country to face steep duties on and other imports. The tariffs have fuelled concerns about broader trade disruptions and...

FDA Grants Complete Approval To Moderna’s COVID-19 Vaccine For Children As Young As 6 Months – Moderna (NASDAQ:MRNA)

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s MRNA supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.The company’s COVID-19 vaccine, mRNA-1273, was previously available...

US Dollar Holds Steady as Trump Threatens 50% Tariffs on Brazil

Trump announces fresh round of tariffs on Brazil and smaller nations But only mild risk aversion as Nvidia (NASDAQ:) drives equities higher, hits $4 trillion cap Fed minutes erase July cut bets as doves in the minority, dollar supported Bitcoin hits record high, comes just shy of $112,000 Trump Stuck in...

The Market Everyone Gave Up On Is Crushing Nasdaq 100 In 2025 – Global X MSCI Greece ETF (ARCA:GREK), Invesco QQQ Trust, Series 1...

Greece's 2010 collapse was so severe it leased islands, gutted public jobs and pensions, while some abroad even joked about selling the Acropolis to appease creditors.Fast forward 15 years, and the picture couldn't be more different.The Athens Stock Exchange has soared nearly 34% year-to-date, making Greece the...

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study – Pfizer (NYSE:PFE)

Pfizer Inc. PFE and Astellas Pharma Inc. ALPMF ALPMY on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence...

Why Is AbbVie Stock Trading Higher On Thursday? – AstraZeneca (NASDAQ:AZN), AbbVie (NYSE:ABBV)

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.“Multispecifics including trispecific antibodies represent...

Dynamic Hedging and FX Risk Analysis Within Tactical Asset Allocation Rules

Often, investors fully hedge their portfolios for currency risk. This can lead to significant drag in performance for currencies with negative carry. However, not hedging the foreign currency exposure can lead to significant drawdowns, especially for conservative investments. In this paper, we consider a conservative, global tactical...

German CPI Confirmed at 2.0%, Euro Drifting, FOMC Split Over Cuts

The euro continues to have a quiet week and is drifting for a third consecutive day. In the European session, is trading at 1.1730, up 0.09% on the day.German Inflation Dips to 2% as food, Energy Prices FallGerman inflation rose 2.0% y/y in June, in line...

Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble? – Klotho Neurosciences (NASDAQ:KLTO)

Shares of Klotho Neurosciences, Inc. KLTO have soared more than 1000% over the past three months on promising results and breakthrough hopes. Klotho stock was in the spotlight again Thursday after announcing an FDA nod on its ALS treatment candidate. What's Driving The Rally: Klotho announced it has received...

Eurozone Economic Weakness Laid Bare as US Front-Loading Effects Wane

Eurozone data remains volatile amid trade war developments, but the underlying trend is still sluggish. Uncertainty is slowing domestic demand, which contributes to our expectation of a further rate cut from the European Central Bank in SeptemberEurozone Economy Shows Further Weakness in the Second QuarterThe eurozone economy...

SeaStar Medical’s QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka – Johnson & Johnson...

When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern. That's particularly true regarding pediatric AKI – each year, about 4,000 children with AKI require continuous renal replacement therapy (RRT), with a mortality rate of approximately 51-58%. Many of those...

Why Are Biotech Stocks Ultragenyx And Mereo Facing A Sell-Off? – Ultragenyx Pharmaceutical (NASDAQ:RARE), Mereo BioPharma Group (NASDAQ:MREO)

Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday.What Happened?The companies on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward...